Canada advises Pfizer in its proposed US$2.26bn acquisition of Trillium Therapeutics Inc., reinforcing their commitment to the pursuit of science

Our Toronto, Ottawa, Calgary and Vancouver offices are advising Pfizer in its proposed acquisition of Trillium Therapeutics Inc. for implied equity value of US$2.26bn. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for $18.50 per share, in cash. The transaction reinforces Pfizer’s commitment to scientific breakthroughs and builds on their strong history of leadership in Oncology while enhancing their hematology portfolio to improve the lives of people living with blood cancers.
Trillium is a clinical stage immuno-oncology company developing innovative cancer treatment therapies that are designed to enhance the patient’s immune system to detect and destroy cancer cells. Its treatment relies on two lead molecules, TTI-622 and TTI-621, which block the signal-regulatory protein α (SIRPα)–CD47 axis, and are emerging as a key immune checkpoint in hematological malignancies. 
Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia, multiple myeloma, and lymphoma. More than one million people worldwide were diagnosed with a blood cancer in 2020, representing almost six percent of all cancer diagnoses globally. In 2020, more than 700,000 people worldwide died from a form of blood cancer.